Aliskiren Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg, 300 mg
Reference Brands: Tekturna(US & EU)
Category:
Heart Disorder
Aliskiren is a direct renin inhibitor that reduces the production of angiotensin I, lowering blood pressure. It decreases cardiovascular risk, improves hypertension control, and helps prevent stroke and heart failure. Benefits include blood pressure reduction, improved cardiovascular health, and enhanced long-term disease management with minimal side effects.
Aliskiren tablets is available in Tablets
and strengths such as 150 mg, 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Aliskiren tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Aliskiren tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Aliskiren tablets, marketed as Tekturna, are approved in the US by the FDA and in the EU via EMA for hypertension management. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and safety data, while the EMA ensures regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional regulations supports timely approval, safe use, and worldwide availability of aliskiren tablets, helping improve blood pressure control and reduce cardiovascular risks globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing